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Abstract
Background: Circulating microRNAs (miRNAs) potentially carry disease-specific information. In 
the current study, we aim to characterize the miRNA signature in plasma from dilated cardiomyopathy 
(DCM) patients and assess the possible correlation between expression levels of circulating miRNAs and 
symptom severity in DCM patients.
Methods: Using microarray-based miRNA expression profiling, we compared the miRNA expression 
levels in plasma samples from 4 DCM patients and 3 healthy controls. The expression levels of selected 
differentially expressed, upregulated miRNAs (miR-3135b, miR-3908 and miR-5571-5p) were vali-
dated independently in plasma samples from 19 DCM patients and 20 controls.
Results: We observed that plasma miR-3135b (p < 0.001), miR-3908 (p < 0.001) and miR-5571-5p 
(p < 0.001) were significantly upregulated in DCM patients. The area under receiver operating char-
acteristic (ROC) curves for the 3 miRNAs ranged from 0.83 to 1.00. Moreover, miR-5571-5p levels in 
plasma were significantly upregulated with severe New York Heart Association (NYHA) classification 
(p < 0.05).
Conclusions: The circulating miRNAs (miR-3135b, miR-3908 and miR-5571-5p) have potential 
as diagnostic biomarkers for DCM. Additionally, miR-5571-5p correlated with NYHA classification. 
(Cardiol J 2017; 24, 1: 65–73)
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Introduction
Dilated cardiomyopathy (DCM), which is 
generally used as an all-encompassing term for 
a non-ischemic cardiomyopathy with depressed left 
ventricular (LV) function, is an important cause of 
sudden cardiac death and heart failure (HF) and 
also the leading indication for cardiac transplanta-
tion in children and adults worldwide [1]. DCM 
may manifest clinically at a wide range of ages and 
is often identified when associated with severe 
limiting symptoms and disability. The diagnosis of 
DCM is usually made with echocardiography, which 
has several disadvantages, including high financial 
costs, limited availability and high interobserver 
variability. The use of circulating biomarkers in 
the diagnostic approach to DCM would offer an 
attractive alternative. MicroRNAs (miRNAs) are 
small, highly conserved, non-coding RNAs, which 
act as endogenous inhibitors of target genes [2–5]. 
MiRNAs have been shown to be key molecular 
players in nearly all cellular processes, including 
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cardiovascular development and pathophysiology 
[6, 7]. Gain or loss of function experiments, expres-
sion arrays and bioinformatic analysis confirmed 
that specific miRNAs played essential roles in the 
biogenesis of DCM [6, 8–13]. This observation 
laid the theoretical foundation of the diagnostic 
application of miRNAs to DCM. Subsequently, 
several studies demonstrated miRNA expression 
differences in various pathological conditions and 
characterized the links between specific miRNAs 
and aspects of pathologies [14, 15]. In addition, 
circulating miRNAs have many requisite features of 
good biomarkers, such as accessibility through non-
invasive methods; a high degree of specificity and 
sensitivity; the ability to differentiate pathologies, 
allowing early detection; sensitivity to relevant 
changes in the disease; a long half-life within the 
sample; and the capability for rapid and accurate 
detection [16]. Therefore, circulating miRNAs have 
potential as new diagnostic biomarkers for DCM.
In the present study, we aimed to characterize 
the miRNA signature in plasma from DCM patients 
compared with healthy controls. We also evalu-
ated the discriminatory power of the significantly 
upregulated miRNAs and correlated them with 
symptom severity in DCM.
Methods
Patients and controls cohort
This study has been approved by the Institution 
Review Board of Beijing Hospital of the Ministry of 
Health, and all subjects provided written informed 
consent before the initiation of any study-related 
procedures. Twenty-three patients with DCM with 
no identifiable or reversible etiology were recruited 
from the Department of Cardiology. Subjects that 
demonstrated persistent (> 3 months) LV systolic 
dysfunction (LV ejection fraction [LVEF] ≤ 40%) 
as assessed by echocardiography were classified 
as patients with DCM for the study. Each DCM 
patient underwent coronary computed tomography 
or coronary angiography, which revealed that no 
coronary stenosis was larger than 50%. In addition, 
a control group, consisting of 23 apparently healthy 
volunteers with no known heart disease, kidney, 
lung or hematologic disorders, were recruited; 
they were age- and gender-matched to the DCM 
group. Exclusion criteria for all participants were 
pregnancy, known or treated malignancies, and 
connective diseases.
All of the clinically relevant data were col-
lected for the DCM group and control group: 
clinical, echocardiographic, electrocardiographic, 
and baseline laboratory, as well as the relevant 
demographic data.
Sample acquisition and handling
An 8 mL aliquot of blood was obtained from all 
participants directly into sodium citrate tubes. The 
whole blood was allowed to stand for ~3 h at –4℃ 
before centrifuging at 1,500 g for 10 min at room 
temperature. The resultant plasma was aliquoted 
into Eppendorf tubes and stored at –70℃.
Clinical biochemical markers
Peripheral venous blood samples were tested 
for the levels of hemoglobin (HGB), creatinine, 
aspartate aminotransferase (AST), and alanine 
aminotransferase (ALT) using standard protocols 
in the core clinical laboratory at Peking Univer-
sity Fifth Hospital. Plasma N-terminal-pro-B type 
natriuretic peptide (NT-proBNP) was measured by 
electrochemiluminescence immunoassay (Elecsys 
proBNP II assay) on an automated Cobas e601 
analyzer according to the manufacturer’s instruc-
tions (Roche Diagnostics GmbH, Mannheim, Ger-
man). The quality controls were measured within 
2-standard deviation values. The range of detection 
for NT-proBNP was 5–3,5000 pg/mL.
Echocardiography
Doppler echocardiographic assessment was 
performed by one of 2 blinded operators in accord-
ance with the European Society of Echocardiogra-
phy recommendations. All data represent the mean 
of 3 measurements on sequential cardiac cycles. 
LVEF was calculated by the Simpson’s method.
RNA extraction
Total RNA was isolated using TRIzol (Invitro-
gen) and purified with RNeasy mini kit (QIAGEN) 
according to manufacturer’s instructions. RNA 
quality and quantity was measured by using a na-
nodrop spectrophotometer (ND-1000, Nanodrop 
Technologies), and RNA Integrity was determined 
by gel electrophoresis.
Microarray processing and analysis
RNA labeling and array hybridization was per-
formed according to Exiqon’s manual. The samples 
were labeled using the miRCURY™ Hy3™/Hy5™ 
Power labeling kit (Exiqon, Vedbaek, Denmark) 
and hybridized on the miRCURY™ LNA Array 
(v.18.0) (Exiqon) according to the manufacturer’s 
guidelines. Following hybridization, the slides 
were obtained and washed several times using 
Wash buffer kit (Exiqon). Then, the slides were 
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scanned using the Axon GenePix 4000B microar-
ray scanner (Axon Instruments, Foster City, CA). 
Scanned images were then imported into GenePix 
Pro 6.0 software (Axon) for grid alignment and data 
extraction. Replicated miRNAs were averaged and 
miRNAs with intensities ≥ 30 in all samples were 
chosen for calculating the normalization factor. 
Expression data were normalized using the median 
normalization. After normalization, the miRNAs 
were considered to be significantly differentially 
expressed only when they exhibited a mean change 
> 2-fold relative to the controls and had a q-value 
< 0.05 between the DCM patients and control groups.
Quantitative reverse-transcription  
polymerase chain reaction (qRT-PCR)
To confirm the findings obtained by analyzing 
the miRNA profiling, we measured the expression 
of upregulated miRNAs using TaqMan qRT-PCR. 
All reactions were carried out using Gene Amp 
PCR System 9700 (Applied Biosystems), according 
to the manufacturer’s recommendations. In brief, 
the reverse transcription reaction was performed 
in 20 μL mixture consisting of 0.3 μL of 10 μM RT 
primer, and 100 ng RNA sample, 2 μL of 2.5 mM 
dNTPs, 0.2 μL MMLV reverse transcriptase, 2 μL 
of 10× reverse transcription buffer, 0.3 μL RNase 
inhibitor, and nuclease-free water. The reaction 
mixture was incubated for 30 min in 16°C, 40 min 
in 42°C, and 5 min in 85°C, and then kept in –20°C. 
Next, qPCR was performed in a final volume of 
10 μL containing 1 μL PCR probe, 2 μL product 
from the RT reaction, 5 μL 2X PCR Master Mix, 
and 2 μL nuclease-free water. The thermal cycle 
started with 10 min at 95°C, followed by 40 cycles 
of 95°C for 10 s and 60°C for 1 min. MiR-191-5p 
was selected as the internal control miRNA to 
normalize the cDNA levels of different samples 
because the concentration of miR-191-5p was ap-
proximately the same in various samples (detailed 
data can be found in Table 1). The threshold cycle 
(Ct) values obtained for each miRNA were then 
normalized to the respective miR-191-5p Ct values 
to obtain the DCt values and eventually used to plot 
relative expression values.
Data analysis and statistics
Data are presented as mean ± standard de-
viation unless indicated otherwise, and plasma 
miRNA levels are presented as fold change relative 
to controls. The miRNA expression fold changes 
were calculated using the arithmetic formula 2 -DDCT.
Continuous clinical variables were compared 
between the two groups by a 2-sided unpaired 
t-test for Gaussian data or Mann-Whitney tests for 
non-Gaussian data. Chi-square tests were used to 
compare categorical clinical variables.
Table 1. MiR-191-5p expression of all samples. 
Coefficient of variation: 1.1%. Circulating miR-
-191-5p is stably expressed across all samples 
and thus is a suitable reference gene for  
normalizing reverse-transcription polymerase 
chain reaction data in this study.
Sample (miR-191-5p) threshold cycle
Control1 22.071 
Control2 22.469 
Control3 22.278 
Control4 21.988 
Control5 22.113 
Control6 21.469 
Control7 22.111 
Control8 21.609 
Control9 21.933 
Control10 21.678 
Control11 21.711 
Control12 21.849 
Control13 22.078 
Control14 21.906 
Control15 21.893 
Control16 22.060 
Control17 21.548 
Control18 21.946 
Control19 21.895 
Control20 21.585 
Dilated1 21.821 
Dilated2 21.977 
Dilated3 22.007 
Dilated4 21.603 
Dilated5 21.714 
Dilated6 21.644 
Dilated7 22.083 
Dilated8 21.887 
Dilated9 21.988 
Dilated10 22.237 
Dilated11 22.042 
Dilated12 21.677 
Dilated13 21.491 
Dilated14 21.465 
Dilated15 21.536 
Dilated16 22.153 
Dilated17 22.372 
Dilated18 22.075 
Dilated19 21.943
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Receiver operating characteristic (ROC) anal-
ysis was carried out for each miRNA validated by 
qRT-PCR, as well as NT-proBNP, and the area 
under the ROC curve (AUC) was calculated to 
evaluate its predictive power for DCM.
Associations between the New York Heart 
Association (NYHA) classification and miRNAs 
were evaluated as follows: a 2-sided unpaired t-test 
was used to compare the miRNAs of samples with 
NYHA classifications of class I–II with the samples 
with NYHA classifications of class III–IV.
Data analysis was performed using the Statis-
tical Package for the Social Sciences (version 19.0; 
SPSS Inc., Chicago, IL, USA). The probability level 
for statistical significance was set at a = 0.05.
Results
Patient characteristics
To select candidate plasma miRNAs for DCM 
detection, we performed an initial genome-wide 
microarray screening of Cohort 1: samples derived 
form 4 DCM patients and 3 matched controls. 
Then, we studied Cohort 2, which was composed 
of 19 DCM patients and 20 controls for independ-
ent validation. The clinical characteristics of the 
DCM patients and controls are shown in Table 2. 
In both cohorts, the two groups were similar 
regarding age, gender, body mass index, HGB, 
liver function (ALT, AST) and renal function (esti-
mated glomerular filtration rate [eGFR]). Predicted 
Table 2. Characteristics of the dilated cardiomyopathy (DCM) group and the control group.
Variables Cohort 1 (screening by microarray) Cohort 2 (validation by qRT-PCR)
Controls
(n = 3)
DCM
(n = 4)
Controls
(n = 20)
DCM
(n = 19)
Age [years] 49.3 ± 8.4 53.7 ± 7.6 56.7 ± 9.1 59.2 ± 13.1
Male 2 (66.7%) 4 (100%) 16 (80%) 16 (84.2%)
Body mass index [kg/m2] 27.2 ± 0.7 25.4 ± 2.7 25.4 ± 2.1 27.0 ± 5.0
Diabetes 0 (0%) 0 (0%) 0 (0%) 2 (10.5%)
Hypertension 0 (0%) 2 (50%) 0 (0%) 12 (63.2%)^
Coronary artery disease 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Atrial fibrillation 0 (0%) 0 (0%) 0 (0%) 9 (47.4%)^
NT-proBNP [pg/mL] 29.7 (5.9–51.4) 1352.8 (772.0–18050.0)# 39.2 (13.4–62.1) 1991.9 (851.5–3706.0)^
LVEF [%] 68.3 ± 2.1 20.5 ± 3.1^ 65.8 ± 4.9 27.5 ± 7.7^
LAD [mm] 31.0 ± 2.6 47.3 ± 5.7^ 34.8 ± 4.1 45.4 ± 6.5^
LVEDD [mm] 44.3 ± 2.3 71.0 ± 9.1^ 45.1 ± 3.3 61.4 ± 7.1^
NYHA grade:
Class I/II 2 (50%) 6 (31.5%)
Class III/IV 2 (50%) 13 (68.5%)
Hemoglobin [g/L] 153.7 ± 27.5 152.8 ± 14.1 153.3 ± 17.2 149.7 ± 19.1
eGFR [mL/min] 116.9 ± 28.5 80.7 ± 11.4 105.5 ± 22.2 91.1 ± 34.9
ALT [U/L] 14.3 ± 1.2 22.0 ± 13.0 29.2 ± 29.2 19.9 ± 9.3
AST [U/L] 19.0 ± 5.6 25.8 ± 7.2 28.3 ± 11.0 23.8 ± 4.6
Beta-blockers 0 (0%) 4 (100%)# 0 (0%) 18 (94.7%)^
ACEI/ARB 0 (0%) 4 (100%)# 0 (0%) 18 (94.7%)^
Spironolactone 0 (0%) 4 (100%)# 0 (0%) 17 (89.5%)^
Digitalis 0 (0%) 3 (75%) 0 (0%) 4 (21.1%)#
Antiplatelet 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Anticoagulation 0 (0%) 0 (0%) 0 (0%) 9 (47.4%)^
ICD/CRT 0 (0%) 1 (25%) 0 (0%) 13 (68.4%)^
Values are shown as mean ± standard deviation, n (%), or median (interquartile range); ^p < 0.05; #p < 0.01; qRT-PCR — quantitative 
reverse-transcription polymerase chain reaction; NT-proBNP — N-terminal-pro-B type natriuretic peptide; LVEF — left ventricular ejection frac-
tion; LAD — left atrial dimension; LVEDD — left ventricular end-diastolic dimension; NYHA — New York Heart Association; eGFR — estimated 
glomerular filtration rate; ALT — alanine aminotransferase; AST — aspartate aminotransferase; ACEI — angiotensin-converting enzyme inhibi-
tor; ARB — angiotensin receptor blockers; ICD — implantable cardioverter-defibrillator; CRT — cardiac resynchronization therapy
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significant changes, reflecting the differences be-
tween DCM patients vs. controls were in LVEF, 
left atrial dimension, LV end-diastolic dimen-
sion and NT-proBNP. In Cohort 2, DCM patients 
had significantly higher levels of NT-proBNP: 
~1,991.9 pg/mL compared with controls: ~39.2 
pg/mL. The LVEF in DCM patients was ~27.5% 
compared with controls with a LVEF of ~65.8%.
MiRNAs microarray of plasma in DCM
To determine the differential miRNA ex-
pression in DCM, we performed plasma miRNA 
microarray analysis with 4 DCM patients and 
3 controls. The microarray covered all human, mouse 
and rat miRNAs annotated in miRBase 18.0, as 
well as all viral miRNAs related to these species. 
The expression profiles of altered miRNAs follow-
ing the genome-wide miRNA microarray showed 
distinctive differences between control and DCM 
patient sample. Of 3,100 miRNAs detected on the 
microarray, 47 miRNAs were found to be differen-
tially expressed in DCM patients compared with 
controls with a fold change > 2 and q < 0.05, among 
which 30 miRNAs were increased. Especially miR-
-3135b, miR-3908, and miR-5571-5p had the most 
significantly increased level.
In some stances, studies have reported that 
the peripheral blood mononuclear cells had similar 
expression of certain gene expression compared to 
pathological tissues. To test whether differentially 
expressed miRNAs of plasma from DCM patients 
mimic the pattern of cardiac miRNAs in end-stage 
HF because of DCM, 9 miRNAs representing the 
cardiac miRNA signature were assessed [10]. 
Surprisingly, we observed that 3 miRNAs (miR-1, 
miR-342, and miR-145) were barely detectable in 
the microarray and that none of the 6 remaining 
miRNAs significantly mirror the cardiac miRNA 
expression pattern (Fig. 1). This indicates that 
circulating miRNA in plasma may be different and 
might have a unique miRNA profile. 
Quantitative RT-PCR analysis  
of plasma miRNAs in DCM
Within Cohort 1, miR-3135b, miR-3908, and 
miR-5571-5p had been shown to have significantly 
upregulated expression. To verify the differential 
expression patterns of these miRNAs, we further 
examined these 3 miRNAs in independent Cohort 2, 
which consisted of 19 DCM patients and 20 con-
trols, by qRT-PCR. Consistent with the aforemen-
tioned results, miR-3135b (p < 0.001), miR-3908 
(p < 0.001), and miR-5571-5p (p < 0.001) were 
significantly upregulated in DCM patients com-
pared with controls (Fig. 2). Furthermore, our 
studies revealed that the miR-3135b, miR-3908, 
and miR-5571-5p expression levels were even 
altered in plasma from patients who had just been 
classified into NYHA class I/II, suggesting that 
plasma miRNAs changes could be observed even 
in patients with mild symptoms.
Furthermore, ROC analysis showed miR- 
-3135b, miR-3908, and miR-5571-5p with significant 
AUC ranged from 0.83 to 1.00, implying that they 
had the discriminatory power to distinguish DCM 
patients from controls (Fig. 3). For comparison 
with the conventional biomarker of HF, we used 
NT-proBNP measurements from these patients 
and NT-proBNP exhibited an AUC value of 0.99. 
Thus, miR-3135b and miR-5571-5p had a similar 
discriminative power for DCM with NT-proBNP.
Because miRNAs are normally excreted by 
the kidney [17], it is possible that miRNA levels in 
the plasma are affected by renal function. To assess 
whether such an effect may have caused a bias in 
our study, we compared the miRNA levels between 
DCM patients whose values for the eGFR were 
above the median and the samples with values that 
were below the median. There was no significant 
(p < 0.05) difference for each miRNA.
Correlation between miRNAs  
and symptom severity in DCM
The 3 miRNAs were tested for a possible as-
sociation with symptom severity in DCM. NYHA 
Figure 1. MiRNA microarray analysis showed that 
6 miRNAs representing the cardiac miRNA signature of 
dilated cardiomyopathy (DCM) patients were not sig-
nificantly differentially expressed in plasma from DCM 
patients compared with plasma from controls. Data pre-
sented as the mean ± standard deviation.
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Figure 3. Receiver operating characteristic (ROC) analysis. ROC curves for miR-3135b (A), miR-3908 (B), and miR-5571-5p (C) 
showed the area under the ROC curve (AUC) to be 1.00, 0.83 (95% CI 0.70–0.96), and 0.91 (95% CI 0.82–1.00), respectively. 
Additionally, N-terminal-pro-B type natriuretic peptide (NT-proBNP) values were used for ROC analysis, and the AUC was 
0.99 (95% CI 0.97–1.00) (D).
Figure 2. Levels of miR-3135b (A), miR-3908 (B), and miR-5571-5p (C) in dilated cardiomyopathy (DCM) patients 
compared with controls by reverse-transcription polymerase chain reaction. Data are presented as fold over internal 
control -miR-191-5p; *p < 0.05.
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classification was based on the severity of symp-
toms and physical activity. We compared the mi-
RNAs between NYHA I–II (n = 6) and NYHA III–IV 
(n = 13). Interestingly, the elevated miR-5571-5p 
(p < 0.05) had a significant association with more 
severe NYHA classification (Fig. 4). In addition, 
miR-3135b and miR-3908 had no significant differ-
ence between NYHA I–II and NYHA III–IV.
Discussion
As the roles of miRNAs in cardiovascular 
diseases are increasingly recognized, we aimed to 
investigate the potential of circulating miRNAs as 
biomarkers in DCM. Our study identified a novel 
cluster of plasma miRNAs (miR-3135b, miR-3908, 
and miR-5571-5p) that was significantly upregu-
lated in DCM patients. In addition, miR-3135b 
and miR-3908 had the discriminatory power to 
differentiate between healthy controls and DCM 
patients nearly similar to the classical NT-proBNP, 
and miR-5571-5p levels had significant correlation 
with symptom severity.
Numerous studies have focused on altera-
tions in the levels and compositions of circulating 
miRNAs in different cardiovascular conditions and 
pathologies [18, 19]. Upon that, we demonstrated 
that plasma miR-3135b, miR-3908 and miR-5571-5p 
might be candidate biomarkers for DCM for the 
first time. Fan et al. [20] identified miR-423-5p as 
a biomarker for HF caused by DCM. However, we 
did not find miR-423-5p levels in DCM to differ 
from those in the controls. The stage of disease 
(acute, chronic, treated or untreated), co-morbidity, 
selected controls and internal references may 
underlie some of the lack of concordance between 
these reports. Furthermore, the ROC analysis 
showed that miR-3135b and miR-5571-5p have 
similar diagnostic powers for DCM as NT-proBNP. 
Thus, miRNA signatures in plasma can potentially 
be developed into biomarkers for HF in the future 
and could act as complements to NT-proBNP in 
some special situations.
The stability of circulating miRNAs raises 
the intriguing speculation that they are taken up 
by distant cells to regulate their gene expression. 
Currently, the potential function of extracellular 
miRNAs is being studied intensively, and some 
studies have confirmed that circulating miRNAs 
may indeed function in cell-to-cell communica-
tion [21, 22]. Therefore, the differential expres-
sion of miRNAs in plasma in DCM might have its 
pathophysiological effect and might be the new 
therapeutic target. Moreover, we discovered that 
plasma miRNA signature was not analogous to 
the cardiac miRNA expression pattern, providing 
new sight into the source and release method of 
circulating miRNAs.
Improvement in symptoms of HF patients 
caused by DCM is one of the two major goals of 
treatment. The symptomatic severity was evaluat-
ed by questionnaire on health-related quality of life, 
6-min walk test, NYHA classification, NT-proBNP 
concentration, and other criteria. However, some 
of the aforementioned methods could be hampered 
by many factors, including educational background, 
depression, and co-morbidity (such as chronic 
obstructive pulmonary disease or osteoarthritis), 
or could have some limitations in particular situa-
tions, including unstable angina pectoris and acute 
myocardial infarction. NT-proBNP was associated 
with a wide variety of cardiac and non-cardiac 
causes [23–26], and some patients with advanced 
HF had normal NT-proBNP levels or had falsely 
low NT-proBNP levels. Our study showed the ex-
pression levels of miR-5571-5p were in line with 
Figure 4. Significant associations between symptom severity and individual microRNA. There are no significant asso-
ciations between New York Heart Association (NYHA) and miR-3135b (A) or miR-3908 (B). Additionally, more severe 
NYHA functional classification is associated with higher miR-5571-5p levels (C); *p < 0.05.
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the NYHA classification. Thus, miR-5571-5p might 
be an objective biomarker for symptomatic severity 
and might be complementary to pre-existing evalu-
ation methods. Furthermore, the clinically guided 
up-titration strategy was reported to be subopti-
mal in achieving target doses of pharmacological 
agents in HF, which limited the therapeutic effects 
of the evidence-based HF medications [27–29]. In 
addition, some meta-analyses concluded that NT- 
-proBNP-guided therapy reduced all-cause mortal-
ity in patients with HF compared with usual clinical 
care [30–32]. Thus, plasma miR-5571-5p might 
be a candidate biomarker to monitor the disease 
progression and guide reasonable therapy.
To investigate the physiological functions of 
the dysregulated miRNAs in response to DCM, the 
potential targets of the 3 miRNAs were predicted, 
sequentially, with the commonly used miRNA 
target prediction software program — TargetScan 
(http://www.targetscan.org/). We found 322 putative 
targets for miR-3135b and 314 putative targets for 
miR-3908; miR-5571-5p was not in the TargetScan 
database. The downregulated genes (targets of the 
upregulated miRNAs) were successfully annotated 
with gene ontology analysis (http://geneontology.
org/). It was easily observed that target genes of 
miR-3135b and miR-3908 were associated with 
HF-related biological processes, especially the 
regulation of cardiac muscle contraction, regulation 
of calcium ion transport, cardiac cell differentiation, 
negative regulation of cellular process, regulation 
of metabolic process, regulation of body fluid levels 
and cardiac myofibril assembly. All of these imply 
that the 3 miRNAs play important roles in HF. Such 
assessment could increase the confidence in the 
potential use of these circulating miRNAs as poten-
tial biomarkers for DCM. Mpreover, it is also a step 
toward further functional studies of these miRNAs.
Limitations of the study
There are several limitations to this study. One 
of the major limitations of this study is the sample 
size, as the results need to be confirmed in a larger 
population. Secondly, we recruited clinically stable 
patients who had not received acute treatment 
for some period of time, and we cannot be certain 
regarding possible interference of chronic medi-
cation. Finally, the precise sources of circulating 
miRNAs remain largely unknown.
Conclusions
In summary, we reported that the expression 
levels of miR-3135b, miR-3908, and miR-5571-5p 
in plasma might be used as biomarkers for DCM, 
and increased miR-5571-5p expression levels were 
found to be associated with a poor NYHA clas-
sification. Our work demonstrates that they are 
promising candidates for this challenge.
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